

DAFTAR PUSTAKA

- Adamichou, C., & Bertsias, G., 2017. Flare in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. *Mediterr J Rheumatol* 28: 16–22.
- Aggarwal, A., & Srivastava, P., 2014. Childhood onset systemic lupus erythematosus : how is it different from adult SLE ?. *International Journal of Rheumatic Diseases*.1-10.
- Akhavan, P.S., Su, J., Lou, W., Gladman, D.D., Urowitz, M.B., & Fortin, P.R., 2013. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. *J. Rheumatol.* 40: 831–841.
- AlSaleem, A., AlE'ed, A., AlSaghier, A., & Al-Mayouf, S.M., 2015. Vitamin D status in children with systemic lupus erythematosus and its association with clinical and laboratory parameters. *Clin. Rheumatol.* 34: 81–84.
- Alshaiki, F., Obaid, E., Almuallim, A., Taha, R., El-haddad, H., & Almoallim, H., 2018. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. *Eur. J. Rheumatol.* 5: 118–126.
- Badsha, H., & Edwards, C.J., 2003. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. *Semin. Arthritis Rheum.* 32: 370–377.
- Behiry, M.E., Salem, M.R., & Alnaggar, A.R., 2019. Assessment of nutritional status and disease activity level in Systemic Lupus Erythematosus patients at a tertiary care hospital. *Rev. Colomb. Reumatol.* 26: 97–104.
- Bertsias George et al, 2012. Systemic Lupus Erythematosus: Pathogenesis and Clinical Features. *Eular On-line Course Rheum. Dis.* 476–505.
- Carter, E.E., Barr, S.G., & Clarke, A.E., 2016. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. *Nat. Rev. Rheumatol.* 12: 605–620.
- Cassidy, J., Petty, R., Laxer, R.M., & Lindsley, C.B., 2011. Textbook of Pediatric Rheumatology, Textbook of Pediatric Rheumatology.16:342-91.
- Cervera, R., Doria, A., Amoura, Z., Khamashta, M., Schneider, M., Guillemain, F., et al., 2014. Patterns of systemic lupus erythematosus expression in Europe. *Autoimmun. Rev.* 13: 621–629.
- Cho, J., Lahiri, M., Teoh, L.K., Dhanasekaran, P., Cheung, P.P., & Lateef, A., 2019. Predicting flares in patients with stable systemic lupus erythematosus. *Semin. Arthritis Rheum.* 49: 91–97.

- Choi, J., Kim, S.T., & Craft, J., 2013. The Pathogenesis of SLE - an Update. *Curr Opin Immunol* 24: 651–657.
- Chowdhary, V.R., 2017. Broad Concepts in Management of Systemic Lupus Erythematosus. *Mayo Clin. Proc.* 92: 744–761.
- Conti, F., Ceccarelli, F., Perricone, C., Miranda, F., Truglia, S., Massaro, L., et al., 2012. Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up Study. *PLoS One* 7: 7–12.
- Corsiero, E., Nerviani, A., Bombardieri, M., & Pitzalis, C., 2016. Ectopic lymphoid structures: Powerhouse of autoimmunity. *Front. Immunol.* 7: 1–6.
- Descloux, E., Durieu, I., Cochat, P., Vital-Durand, D., Ninet, J., Fabien, N., et al., 2009. Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. *Rheumatology* 48: 779–784.
- Dolff, S., Bijl, M., Huitema, M.G., Limburg, P.C., Kallenberg, C.G.M., & Abdulahad, W.H., 2011. Disturbed Th1, Th2, Th17 and T reg balance in patients with systemic lupus erythematosus. *Clin. Immunol.* 141: 197–204.
- Doria, A., Iaccarino, L., Ghirardello, A., Zampieri, S., Arienti, S., Sarzi-Puttini, P., et al., 2006. Long-Term Prognosis and Causes of Death in Systemic Lupus Erythematosus. *Am. J. Med.* 119: 700–706.
- Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J.N., et al., 2019. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann. Rheum. Dis.* 78: 736–745.
- Farkhati, M.Y., Hapsara, S., & Satria, C.D., 2016. Antibodi Anti DS-DNA Sebagai Faktor Prognosis Mortalitas pada Lupus Erimatosus Sistemik. *Sari Pediatr.* 14: 90.
- Fayyaz, A., Igoe, A., Kurien, B.T., Danda, D., James, J.A., Stafford, H.A., et al., 2015. Haematological manifestations of lupus. *Lupus Sci. Med.* 2:e000078.
- Ferretti, C., & La Cava, A., 2016. Overview of the Pathogenesis of Systemic Lupus Erythematosus, Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Elsevier. 8:55-62.
- Floris, A., Piga, M., Cauli, A., & Mathieu, A., 2016. Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. *Autoimmun Rev.* 15(7):656-63.
- Hiraki, L.T., Benseler, S.M., Tyrrell, P.N., Harvey, E., Hebert, D., & Silverman, E.D., 2009. Ethnic differences in pediatric systemic lupus erythematosus. *J. Rheumatol.* 36: 2539–2546.

- Horwitz, D.A., 2008. Regulatory T cells in systemic lupus erythematosus: Past, present and future. *Arthritis Res. Ther.* 10: 1–9.
- Inês, L., Duarte, C., Silva, R.S., Teixeira, A.S., Fonseca, F.P., & Da Silva, J.A.P., 2014. Identification of clinical predictors of flare in systemic lupus erythematosus patients: A 24-month prospective cohort study. *Rheumatol. (United Kingdom)* 53: 85–89.
- Jeong, S.J., Choi, H., Lee, H.S., Han, S.H., Chin, B.S., Baek, J.H., et al., 2009. Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. *Scand. J. Infect. Dis.* 41: 268–274.
- Joo, Y. Bin, Park, S.Y., Won, S., & Bae, S.C., 2016. Differences in clinical features and mortality between childhood-onset and adult-onset systemic lupus erythematosus: A prospective single-center study. *J. Rheumatol.* 43: 1490–1497.
- Jung, J., & Suh, C., 2017. Infection As a Triggering Factor for Sle. *Korean J. Intern. Med.* 32: 429–438.
- Jung, J.H., Soh, M.S., Ahn, Y.H., Um, Y.J., Jung, J.Y., Suh, C.H., et al., 2016. Thrombocytopenia in Systemic Lupus Erythematosus. *Med. (United States)* 95: 1–7.
- Jung, J.Y., & Suh, C.H., 2017. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. *Korean J. Intern. Med.* 32: 429–438.
- Kasjmir, Y., Handono, K., Wijaya, L., Hamijoyo, L., Albar, Z., Kalim, H., et al., 2011. Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. Perhimpunan Reumatologi Indonesia, Jakarta.
- Katsicas, M.M., Borgia, E.R., & Russo, R.A., 2013. SAT0472 Accuracy of Systemic Lupus International Collaborating Clinics Classification Criteria Applied to Juvenile Systemic Lupus Erythematosus Patients. *Ann. Rheum. Dis.* 72: A741.2-A741.
- Khanna, S., Pal, H., Pandey, R.M., & Handa, R., 2004. The relationship between disease severity and quality of life in systemic lupus erythematosus. *Rheumatology* 43: 1536–1540.
- Kim, J.W., Kim, Y.Y., Lee, H., Park, S.H., Kim, S.K., & Choe, J.Y., 2017. Risk of retinal toxicity in longterm users of hydroxychloroquine. *J. Rheumatol.* 44: 1674–1679.
- Klein-gitelman, A.T.M.S., 2016. An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus. *Rheumatol. Ther.* 3: 209–219.
- Kono, D.H., Haraldsson, M.K., Lawson, B.R., Pollard, K.M., Yi, T.K., Du, X., et al., 2009. Endosomal TLR signaling is required for anti-nucleic acid and

- rheumatoid factor autoantibodies in lupus. *Proc. Natl. Acad. Sci. U. S. A.* 106: 12061–12066.
- Kontaki, E., & Boumpas, D.T., 2010. Innate immunity in systemic lupus erythematosus: Sensing endogenous nucleic acids. *J. Autoimmun.* 35: 206–211.
- Kuhn, A., Bonsmann, G., Anders, H.J., Herzer, P., Tenbrock, K., & Schneider, M., 2015. The Diagnosis and Treatment of Systemic Lupus Erythematosus. *Dtsch. Arztebl. Int.* 112: 423–432.
- Lastrup, H., Voss, A., Green, A., & Junker, P., 2010. SLE disease patterns in a Danish population-based lupus cohort: An 8-year prospective study. *Lupus* 19: 239–246.
- Lehman, T., Nuruzzaman, F., & Taber, S., 2016. Systemic Lupus Erythematosus: Etiology, Pathogenesis, Clinical Manifestations, and Management. *Handb. Syst. Autoimmune Dis.* 11: 173–189.
- Levy, D.M., Peschken, C.A., Tucker, L.B., Chédeville, G., Huber, A.M., Pope, J.E., et al., 2013. Influence of ethnicity on childhood-onset systemic lupus erythematosus: Results from a multiethnic multicenter Canadian cohort. *Arthritis Care Res.* 65: 152–160.
- Listiyono, F., Sumadiono, Satria, C.D., & Murni, I.K., 2019. Predictors of mortality in children with systemic lupus erythematosus. *Paediatr. Indones. Orig. Artic.* 59: 1–6.
- Lövgren, T., Eloranta, M.L., Kastner, B., Wahren-Herlenius, M., Alm, G. V., & Rönnblom, L., 2006. Induction of interferon- α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome auto antigen - Associated RNA. *Arthritis Rheum.* 54: 1917–1927.
- Lu, L.J., Wallace, D.J., Ishimori, M.L., Scofield, R.H., & Weisman, M.H., 2010. Review: Male systemic lupus erythematosus: A review of sex disparities in this disease. *Lupus* 19: 119–129.
- Lythgoe, H., Morgan, T., Heaf, E., Lloyd, O., Al-Abadi, E., Armon, K., et al., 2017. Evaluation of the ACR and SLICC classification criteria in juvenile-onset systemic lupus erythematosus: A longitudinal analysis. *Lupus* 26: 1285–1290.
- Ma, J., Yu, J., Tao, X., Cai, L., Wang, J., & Zheng, S.G., 2010. The imbalance between regulatory and IL-17-secreting CD4 + T cells in lupus patients. *Clin. Rheumatol.* 29: 1251–1258.
- Mesa, M.A., & Vasquez, G., 2013. NETosis. *Autoimmune Dis.* 1–7.
- Mikdashi, J., & Nived, O., 2015. Measuring disease activity in adults with systemic lupus erythematosus: The challenges of administrative burden and

- responsiveness to patient concerns in clinical research. *Arthritis Res. Ther.* 17(1):183.
- Mosca, M., Tani, C., Carli, L., & Bombardieri, S., 2011. Glucocorticoids in systemic lupus erythematosus. *Clin. Exp. Rheumatol.* 29: 24–27.
- Muñoz-Grajales, C., González, L.A., Alarcón, G.S., & Acosta-Reyes, J., 2016. Gender differences in disease activity and clinical features in newly diagnosed systemic lupus erythematosus patients. *Lupus* 25: 1217–1223.
- Murphy, G., & Isenberg, D., 2013. Effect of gender on clinical presentation in systemic lupus erythematosus. *Rheumatol. (United Kingdom)* 52: 2108–2115.
- Nikpour, M., Urowitz, M.B., Ibañez, D., & Gladman, D.D., 2009. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. *Arthritis Care Res.* 61: 1152–1158.
- Pan, L., Lu, M.P., Wang, J.H., Xu, M., & Yang, S.R., 2019. Immunological pathogenesis and treatment of systemic lupus erythematosus. *World J. Pediatr.* 16(1):19-30.
- Parikh, S. V., Nagaraja, H.N., Hebert, L., & Rovin, B.H., 2014. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. *Clin. J. Am. Soc. Nephrol.* 9: 279–284.
- Parodis, I., Tamirou, F., & Houssiau, F.A., 2020. Prediction of prognosis and renal outcome in lupus nephritis. *Lupus Sci. Med.* 7: 1–6.
- Peng, L., Wang, Z., Li, M., Wang, Y., Xu, D., Wang, Q., et al., 2017. Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study. *Clin. Rheumatol.* 36: 2727–2732.
- Petri, M.A., Vollenhoven, R.F. Van, Buyon, J., Levy, R.A., Navarra, S. V., Cervera, R., et al., 2013. Baseline Predictors of Systemic Lupus Erythematosus Flares Data From the Combined Placebo Groups in the Phase III Belimumab Trials 65: 2143–2153.
- Pluchinotta, F.R., Schiavo, B., Vittadello, F., Martini, G., Perilongo, G., & Zulian, F., 2007. Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes. *Lupus* 16: 550–555.
- Pocovi-gerardino, G., & Callejas-rubio, J., 2019. The Prognostic Nutritional Index and Nutritional Risk Index Are Associated with Disease Activity in Patients with Systemic Lupus Erythematosus 1–9.
- Ponticelli, C., & Moroni, G., 2017. Hydroxychloroquine in systemic lupus erythematosus (SLE). *Expert Opin. Drug Saf.* 16: 411–419.
- Rabbani, M.A., Habib, H.B., Islam, M., Ahmad, B., Majid, S., Saeed, W., et al., 2009. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. *Lupus* 18: 848–855.

- Rees, F., Doherty, M., Grainge, M.J., Lanyon, P., & Zhang, W., 2017. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. *Rheumatol. (United Kingdom)* 56: 1945–1961.
- Rönnblom, L., & Pascual, V., 2008. The innate immune system in SLE: Type I interferons and dendritic cells. *Lupus* 17: 394–399.
- Ruiz-Irastorza, G., Danza, A., & Khamashta, M., 2012. Glucocorticoid use and abuse in SLE. *Rheumatol. (United Kingdom)* 51: 1145–1153.
- Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M.A., 2010. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. *Ann. Rheum. Dis.* 69: 20–28.
- Saleh, A.M., Kurniati, N., & Syarif, B.H., 2016. Penilaian Aktivitas Penyakit Lupus Eritematosus Sistemik dengan Skor SLEDAI di Departemen Ilmu Kesehatan Anak RSCM. *Sari Pediatr.* 16: 292.
- Samy, E., Wax, S., Huard, B., Hess, H., & Schneider, P., 2017. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. *Int. Rev. Immunol.* 36: 3–19.
- Soto, M.E., Vallejo, M., Guillén, F., Simón, J.A., Arena, E., & Reyes, P.A., 2004. Gender impact in systemic lupus erythematosus. *Clin. Exp. Rheumatol.* 22: 713–721.
- Stojan, G., & Petri, M., 2017. The Risk Benefit Ratio of Glucocorticoids in SLE: Have Things Changed over the Past 40 years? *Curr. Treat. Options Rheumatol.* 3: 164–172.
- Tan, T.C., Fang, H., Magder, L.S., & Petri, M.A., 2012. Differences between male and female systemic lupus erythematosus in a multiethnic population. *J. Rheumatol.* 39: 759–769.
- Teh, C.L., & Ling, G.R., 2013. Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. *Lupus* 22: 106–111.
- Tian, J., Avalos, A.M., Mao, S.Y., Chen, B., Senthil, K., Wu, H., et al., 2007. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat. Immunol.* 8: 487–496.
- Tseng, C.E., Buyon, J.P., Kim, M., Belmont, H.M., Mackay, M., Diamond, B., et al., 2006. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 54: 3623–3632.
- Tsokos, G.C., Lo, M.S., Reis, P.C., & Sullivan, K.E., 2016. New insights into the immunopathogenesis of systemic lupus erythematosus. *Nat. Rev. Rheumatol.* 12: 716–730.



- Visser, Karen; Houssiau, Frederic A.; Silva, Jose Antonio P. da; Vollenhoven, R. van, 2007. Systemic Lupus Erythematosus : Treatment module 18. *EULAR on-line course Rheum. Dis.* 71: 317–321.
- Wang, Z., Wang, Y., Zhu, R., Tian, X., Xu, D., Wang, Q., et al., 2015. Long-term survival and death causes of systemic lupus erythematosus in China: A systemic review of observational studies. *Med. (United States)* 94: e794.
- Weiss, J.E., 2012. Pediatric systemic lupus erythematosus: More than a positive antinuclear antibody. *Pediatr. Rev.* 33(2):62-73.
- Yang, J., Chu, Y., Yang, Xue, Gao, D., Zhu, L., Yang, Xinrong, et al., 2009. Th17 and natural treg cell population dynamics in systemic lupus erythematosus. *Arthritis Rheum.* 60: 1472–1483.
- Yurkovich, M., Vostretsova, K., Chen, W., & Aviña-Zubieta, J.A., 2014. Overall and cause-specific mortality in patients with systemic lupus erythematosus: A meta-analysis of observational studies. *Arthritis Care Res.* 66: 608–616.
- Zhang, Z., Kyttaris, V.C., & Tsokos, G.C., 2009. The Role of IL-23/IL-17 Axis in Lupus Nephritis. *J. Immunol.* 183: 3160–3169.
- Zonana-Nacach, A., Barr, S.G., Magder, L.S., & Petri, M., 2000. Damage in systemic lupus erythematosus and its association with corticosteroids. *Arthritis Rheum.* 43: 1801–1808.